BACKGROUND: Fear of recurrence (FoR) is a widespread problem among breast cancer survivors. So far, little is known about prevalence, determinants, and consequences of FoR specifically in long-term breast cancer survivors, even though it was found to be one of the most important concerns in this group. METHODS: Analyses are based on data of several population-based cohorts of long-term breast cancer survivors, recruited by six German cancer registries. Overall, 2671 women were included in the analyses. FoR was assessed using the short form of the Fear of Progression Questionnaire. Potential determinants of moderate/high FoR and the association with depression and quality of life (QoL) were explored via multiple logistic and linear regression. RESULTS: Even though the majority of women reported low levels of FoR (82%), a substantial percentage experienced moderate (11%) and high (6%) FoR. Younger age (odds ratio = 3.00, confidence intervals = 1.91-4.73 for women below age 55 years) and considering oneself as a tumor patient (odds ratio = 3.36, confidence intervals = 2.66-4.25) were found to exhibit the strongest associations with moderate/high FoR. Overall, psychosocial and sociodemographic factors played a far bigger role in FoR than clinical factors. Higher FoR was associated with higher depression and lower QoL. CONCLUSION: Fear of recurrence (mostly low levels) is highly prevalent among long-term breast cancer survivors and can negatively affect QoL and well-being. Therefore, it should be given appropriate consideration in research and clinical practice. As specifically younger women tended to be impacted by FoR, it is crucial to be particularly attentive to specific needs of younger survivors.
BACKGROUND: Fear of recurrence (FoR) is a widespread problem among breast cancer survivors. So far, little is known about prevalence, determinants, and consequences of FoR specifically in long-term breast cancer survivors, even though it was found to be one of the most important concerns in this group. METHODS: Analyses are based on data of several population-based cohorts of long-term breast cancer survivors, recruited by six German cancer registries. Overall, 2671 women were included in the analyses. FoR was assessed using the short form of the Fear of Progression Questionnaire. Potential determinants of moderate/high FoR and the association with depression and quality of life (QoL) were explored via multiple logistic and linear regression. RESULTS: Even though the majority of women reported low levels of FoR (82%), a substantial percentage experienced moderate (11%) and high (6%) FoR. Younger age (odds ratio = 3.00, confidence intervals = 1.91-4.73 for women below age 55 years) and considering oneself as a tumorpatient (odds ratio = 3.36, confidence intervals = 2.66-4.25) were found to exhibit the strongest associations with moderate/high FoR. Overall, psychosocial and sociodemographic factors played a far bigger role in FoR than clinical factors. Higher FoR was associated with higher depression and lower QoL. CONCLUSION: Fear of recurrence (mostly low levels) is highly prevalent among long-term breast cancer survivors and can negatively affect QoL and well-being. Therefore, it should be given appropriate consideration in research and clinical practice. As specifically younger women tended to be impacted by FoR, it is crucial to be particularly attentive to specific needs of younger survivors.
Authors: Wendy G Lichtenthal; Geoffrey W Corner; Elizabeth T Slivjak; Kailey E Roberts; Yuelin Li; William Breitbart; Stephanie Lacey; Malwina Tuman; Katherine N DuHamel; Victoria S Blinder; Courtney Beard Journal: Cancer Date: 2017-01-05 Impact factor: 6.860
Authors: Danielle Petricone-Westwood; Georden Jones; Brittany Mutsaers; Caroline Séguin Leclair; Christina Tomei; Geneviève Trudel; Andreas Dinkel; Sophie Lebel Journal: Int J Behav Med Date: 2019-02
Authors: Sophie Elisabeth Groß; Anika Nitzsche; Tristan D Gloede; Lena Ansmann; Richard Street; Holger Pfaff; Melanie Neumann; Markus Wirtz; Walter Baumann; Stephan Schmitz; Nicole Ernstmann Journal: Support Care Cancer Date: 2014-09-25 Impact factor: 3.603
Authors: S Sarkar; A Scherwath; L Schirmer; F Schulz-Kindermann; K Neumann; M Kruse; A Dinkel; S Kunze; F Balck; N Kröger; U Koch; A Mehnert Journal: Bone Marrow Transplant Date: 2014-07-07 Impact factor: 5.483
Authors: Christine Miaskowski; Steven M Paul; Judy Mastick; Gary Abrams; Kimberly Topp; Betty Smoot; Kord M Kober; Margaret Chesney; Melissa Mazor; Grace Mausisa; Mark Schumacher; Yvette P Conley; Jennifer Henderson Sabes; Steven Cheung; Margaret Wallhagen; Jon D Levine Journal: J Pain Symptom Manage Date: 2018-03-07 Impact factor: 3.612
Authors: Louise Sharpe; J Turner; J E Fardell; B Thewes; A B Smith; J Gilchrist; J Beith; A Girgis; S Tesson; S Day; K Grunewald; P Butow Journal: J Cancer Surviv Date: 2019-07-25 Impact factor: 4.442